Corcept Therapeutics (NASDAQ:CORT – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They presently have a $165.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 44.94% from the company’s current price.
Other research analysts also recently issued reports about the stock. Wall Street Zen raised shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Piper Sandler reiterated an “overweight” rating and set a $165.00 target price (up from $88.00) on shares of Corcept Therapeutics in a research note on Thursday, July 30th. UBS Group set a $135.00 price target on Corcept Therapeutics in a report on Thursday, May 28th. Truist Financial initiated coverage on Corcept Therapeutics in a research report on Tuesday, August 18th. They issued a “buy” rating and a $164.00 price target on the stock. Finally, Wolfe Research downgraded Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective for the company. in a research note on Monday, July 27th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $138.17.
Check Out Our Latest Research Report on Corcept Therapeutics
Corcept Therapeutics Trading Down 0.9%
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.34. The business had revenue of $256.15 million for the quarter, compared to analysts’ expectations of $221.15 million. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The business’s revenue was up 31.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.29 earnings per share. On average, equities research analysts anticipate that Corcept Therapeutics will post 2.02 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, Director James Wilson sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $110.69, for a total value of $1,106,900.00. Following the sale, the director owned 1,064,543 shares of the company’s stock, valued at approximately $117,834,264.67. This represents a 0.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kimberly Park sold 26,685 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $122.55, for a total transaction of $3,270,246.75. Following the sale, the director directly owned 30,000 shares in the company, valued at $3,676,500. This represents a 47.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 446,119 shares of company stock valued at $50,644,753. 20.70% of the stock is owned by company insiders.
Institutional Investors Weigh In On Corcept Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Corcept Therapeutics during the second quarter valued at approximately $1,080,964,000. First Trust Advisors LP increased its position in shares of Corcept Therapeutics by 213.5% during the 1st quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock valued at $87,609,000 after purchasing an additional 1,480,059 shares during the period. Geode Capital Management LLC raised its stake in shares of Corcept Therapeutics by 38.0% in the 4th quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after buying an additional 734,646 shares in the last quarter. Norges Bank bought a new stake in shares of Corcept Therapeutics in the 4th quarter worth $24,213,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Corcept Therapeutics in the second quarter valued at $49,185,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.
Trending Headlines about Corcept Therapeutics
Here are the key news stories impacting Corcept Therapeutics this week:
- Positive Sentiment: The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorization for Lifyorli plus nab-paclitaxel. The opinion supports Corcept’s expansion into ovarian cancer and could create a new commercial opportunity outside its existing Cushing’s syndrome business. Final approval from the European Commission is still required. Corcept receives CHMP recommendation for Lifyorli
- Positive Sentiment: Zacks Research raised several long-term earnings forecasts, including FY2027 EPS to $2.05 from $1.91 and FY2028 EPS to $4.31 from $4.07. Analysts also increased estimates for select 2026 and 2027 quarters, suggesting improving expectations for Corcept’s growth and pipeline contribution.
- Neutral Sentiment: Corcept previously reported strong quarterly results, with revenue up 31.7% year over year to $256.15 million and EPS of $0.36 versus the $0.02 consensus estimate. However, the stock trades at a very elevated earnings multiple, making it sensitive to profit-taking and changes in growth expectations.
- Negative Sentiment: Director James Wilson sold 10,000 shares for approximately $1.11 million, reducing his direct ownership by 0.93%. A separate insider, Joseph Lyon, also sold 10,000 shares, cutting his position by about 64%. Although insider sales do not necessarily signal deteriorating fundamentals, they can weigh on sentiment, particularly after a substantial share-price advance. Corcept insider selling report
Corcept Therapeutics Company Profile
Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company’s research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases.
Corcept’s commercial product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.
Read More
- Five stocks we like better than Corcept Therapeutics
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
